Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 3
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Biopharmaceuticals from microorganisms: from production to purification BJM
Jozala,Angela Faustino; Geraldes,Danilo Costa; Tundisi,Louise Lacalendola; Feitosa,Valker de Araújo; Breyer,Carlos Alexandre; Cardoso,Samuel Leite; Mazzola,Priscila Gava; Oliveira-Nascimento,Laura de; Rangel-Yagui,Carlota de Oliveira; Magalhães,Pérola de Oliveira; Oliveira,Marcos Antonio de; Pessoa Jr,Adalberto.
ABSTRACT The use of biopharmaceuticals dates from the 19th century and within 5-10 years, up to 50% of all drugs in development will be biopharmaceuticals. In the 1980s, the biopharmaceutical industry experienced a significant growth in the production and approval of recombinant proteins such as interferons (IFN α, β, and γ) and growth hormones. The production of biopharmaceuticals, known as bioprocess, involves a wide range of techniques. In this review, we discuss the technology involved in the bioprocess and describe the available strategies and main advances in microbial fermentation and purification process to obtain biopharmaceuticals.
Tipo: Info:eu-repo/semantics/article Palavras-chave: Biopharmaceuticals; Fermentation process; Biotechnology; Upstream process; Downstream process.
Ano: 2016 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822016000500051
Imagem não selecionada

Imprime registro no formato completo
Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals BJPS
Pucca,Manuela Berto; Bertolini,Thaís Barboza; Barbosa,José Elpidio; Galina,Simone Vasconcelos Ribeiro; Porto,Geciane Silveira.
Monoclonal antibodies represent the fastest growing class of biopharmaceutical products and have a host of applications in medical research, diagnosis, therapy, and basic science. The production of recombinant monoclonal antibodies has revolutionized the generation of immunoglobulins, and their use represents a strategic breakthrough, affecting the global pharmaceutical market for therapeutic proteins. In the present work, a review of scFv, and the number of related patents, has been carried out. The results show that several countries have scFv patents, most notably the United States, China and United Kingdom. The target of these scFv antibodies was also assessed and the results demonstrate that most are directed toward cancer therapy.
Tipo: Info:eu-repo/semantics/article Palavras-chave: Monoclonal antibodies; Recombinant antibodies; ScFv; Biopharmaceuticals.
Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000100005
Imagem não selecionada

Imprime registro no formato completo
Valuing Intellectual Property Rights in an Imperfectly Competitive Market: A Biopharming Application AgEcon
Kostandini, Genti; Mills, Bradford F..
Small research firms developing biotechnology applications often focus on establishing intellectual property rights (IPRs), which can then be sold to more established firms with existing market channels. This paper presents a method for valuing the IPRs for an innovation that lowers product production costs below those associated with the patented process of a monopolist. The application to Glucocerebrosidase enzyme from transgenic tobacco suggests an IPRs value of about $1.75 billion. Despite the innovator’s market power, significant surplus gains also accrue to consumers. Further, U.S. antitrust laws that prohibit IPRs acquisition by the current monopolist increase consumer welfare by almost 50%.
Tipo: Journal Article Palavras-chave: Biopharmaceuticals; Biopharming; Economic surplus; Imperfect competition; Intellectual property rights; Agribusiness; Demand and Price Analysis; Financial Economics; Marketing; D23; M13; D43; D60.
Ano: 2009 URL: http://purl.umn.edu/56641
Registros recuperados: 3
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional